This is an unofficial translation of a notice to the Annual General Meeting in
Today, the 15th of
Adoption of the income statement and balance sheet
The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet.
Allocation of the company's profit or loss
The AGM resolved to dispose of the company's results according to the adopted balance sheet, in accordance with the Board's proposal in the annual report with no dividend to be paid for the financial year 2022/2023.
Discharge of liability for board members and CEO
The AGM resolved to discharge the members of the board of directors and the managing director from liability for the financial year of 2022/2023.
Determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors
The AGM resolved that the board of directors consist of four (4) ordinary board members and no deputy board member and that one auditor is determined, and no deputy auditors.
Determination of fees for members of the board of directors and auditors
The AGM resolved that the board remuneration should amount to
The AGM resolved that the auditors' fees should be paid according to approval invoice in accordance with customary charging standards.
Election of the board of directors and accounting firm or auditor
The AGM resolved that Derek Simmross,
The AGM resolved that the company's audit firm Öhrlings
For more information on
Derek Simmross, CEO,
E-mail: info@odipharma.com
https://news.cision.com/odi-pharma/r/announcement-from-the-annual-general-meeting-in-odi-pharma-ab--publ-,c3894357
(c) 2023 Cision. All rights reserved., source